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ABSTRACT
HIV-1 Vif (viral infectivity factor) is associated
with the assembly complexes and packaged at low
level into the viral particles, and is essential for viral
replication in non-permissive cells. Viral particles
produced in the absence of Vif exhibit structural
defects and are defective in the early steps of
reverse transcription. Here, we show that Vif is able
to anneal primer tRNA
Lys3 to the viral RNA, to
decrease pausing of reverse transcriptase during
(–) strand strong-stop DNA synthesis, and to
promote the first strand transfer. Vif also stimulates
formation of loose HIV-1 genomic RNA dimers.
These results indicate that Vif is a bona fide RNA
chaperone. We next studied the effects of Vif
in the presence of HIV-1 NCp, which is a well-
established RNA chaperone. Vif inhibits NCp-
mediated formation of tight RNA dimers and
hybridization of tRNA
Lys3, while it has little effects
on NCp-mediated strand transfer and it collaborates
with nucleocapsid (NC) to increase RT processivity.
Thus, Vif might negatively regulate NC-assisted
maturation of the RNA dimer and early steps of
reverse transcription in the assembly complexes,
but these inhibitory effects would be relieved after
viral budding, thanks to the limited packaging of
Vif in the virions.
INTRODUCTION
In addition to the structural gag, pol and env genes, the
human immunodeﬁciency virus type 1 (HIV-1) genome
contains several regulatory genes: tat, rev, nef, vpr, vif and
vpu. The HIV-1 Vif (viral infectivity factor) protein,
ﬁrst considered as an accessory factor, is a positive
modulator of viral infectivity in several cell types. In
particular, Vif is required for eﬃcient HIV-1 replication in
so called ‘non-permissive’ cells such as primary CD4+T
lymphocytes and macrophages and some T-cell lines (H9,
HUT78), whereas HIV-1 lacking vif (HIV-1 vif) can
replicate in ﬁbroblasts and most T-cell lines termed
‘permissive’ (1–6).
This cell type-dependent requirement for Vif can be
explained by the expression of APOBEC3G and
APOBEC3F, two cellular inhibitors of HIV-1 replication,
in non-permissive cells (5,7). APOBEC3G/3F are
members of a large family of cytidine deaminases (8).
In the absence of Vif, APOBEC3G/3F associate with
Gag and RNA during viral assembly and are
packaged into virions (9–14). APOBEC3G/3F induce
hypermutation of the HIV-1 genome by mediating
deamination of cytidine to uracil on the newly synthesized
(–) strand DNA during reverse transcription, thus
leading to guanosine to adenosine transitions in the viral
genome (9,15–17). Independently from their catalytic
activity, APOBEC3G/3F factors also impair particle
infectivity by aﬀecting virion morphology and by
destabilizing the reverse transcription complex (18–21).
Vif counteracts the antiviral activity of APOBEC3G/3F
by several mechanisms. Vif seems to directly impair
packaging of APOBEC3G/3F by an unknown mechanism
(10,22–24), induces degradation of APOBEC3G/3F
through the ubiquitination-proteasome pathway
(22,25–27), and negatively regulates APOBEC3G/3F
translation (10,22,23).
Vif is part of a large cytoplasmic ribonucleoprotein
(RNP) complex and it is now usually accepted that Vif is
packaged into viral particles through interactions with the
viral genomic RNA, co-packaged cellular RNAs and the
nucleocapsid (NC) domain of Gag (14,28–33). Vif
defective viruses produced from non-permissive cells
display defects not only at early assembly events but
also at post-entry steps of infection, resulting in a failure
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Moreover, viral particles produced in the absence of Vif
show structural defects such as aberrant core morphology
and reduced stability (37,40,41). In particular, NC and
reverse transcriptase (RT) were found to be less stably
associated with viral cores in the absence of Vif (40),
explaining in part why  vif virions are defective in the
reverse transcription step (29,36,42,43). Initiation of
reverse transcription is completely impaired in  vif
viruses, suggesting that Vif may serve as an auxiliary
factor for HIV-1 RT (44) and allows formation of a
functional RNP (30). It has also been shown that Vif is
able to modulate viral protease (PR) activity and the
proteolytic processing of the Gag precursor at the p2/NC
site, leading to the possibility that virion incorporation of
Vif could stabilize NC intermediates (45–47).
Considering that NCp7 (48–50) and Vif (44) are both
involved in the reverse transcription process and in
structural rearrangements of HIV-1 RNA (29), we were
interested to know whether Vif could modulate RNA
dimerization, a prerequisite for RNA packaging (51,52),
and the early steps of reverse transcription either alone or
in presence of various intermediate processing products of
Gag (NCp7, NCp9 and NCp15). In the absence of NC
proteins, we found that Vif possesses RNA chaperone
activity, resembling but distinct from the chaperone
properties of NCp proteins with respect to RNA
dimerization, hybridization of tRNA
lys3 to the PBS,
initiation of reverse transcription by RT and the ﬁrst
strand transfer. Surprisingly, Vif inhibited the initiation
phase of reverse transcription. At high Vif/NCp ratio
(1/3), Vif also inhibited NCp-induced maturation of the
RNA dimer and tRNA
lys3 annealing, whereas both NCp
and Vif contributed to increase the processivity of RT. Vif
had modest eﬀects on the NCp-induced strand transfer
reaction. At low Vif/NCp ratio (1/30), Vif had very limited
eﬀects on reverse transcription. Considering that Gag
maturation is a highly ordered process that can be
modulated by Vif (47), and that Vif is a RNA chaperone
inﬂuencing RNA dimerization, tRNA annealing, RT
processivity, and the ﬁrst strand transfer, our results
suggest that during the assembly steps, Vif might be a
negative temporal regulator of RNA dimerization and
packaging, preventing premature initiation of reverse
transcription, while promoting tRNA annealing, a process
that could be aﬀected by APOBEC3F/3G.
MATERIALS AND METHODS
RNA template andprimers
The donor and acceptor RNAs, corresponding respec-
tively to nucleotides 1–311 and 8607–9229 of HIV-1
genomic RNA (Mal isolate) were synthesized by
in vitro transcription of plasmids pJCB and pFB1 using
T7 RNA polymerase and puriﬁed as previously described
(53). Plasmid containing a 3-nt substitution in the self-
complementary sequence of the RNA dimerization initia-
tion site (DIS) loop (pDIS-AAA) (54) was digested by
RsaI prior to in vitro transcription to generate mutated
RNA 1–311. RNA 1–615 used in the dimerization assays
has been obtained after digestion of plasmid pHIV_615 by
PvuII (55). Prior to 50-end labeling, 10mg of tRNA
Lys3
puriﬁed from beef liver (56) were denatured for 2min at
908C in 25mM Tris–HCl pH 8, 0.1% SDS (wt/vol), 15%
(vol/vol) formamide, cooled on ice and incubated with
1000U of BAP (Fermentas) at 708C for 1h. After
phenol/chloroform extraction and ethanol precipitation,
the dephosphorylated tRNA
lys3 was puriﬁed by denatur-
ing polyacrylamide gel electrophoresis (PAGE).
Dephosphorylated tRNA
lys3 (450ng) was incubated
5min at 708C, cooled at room temperature and radi-
olabeled using 15U of phage T4 polynucleotide kinase
(PNK, New England Biolabs) and 100mCi of [g-
32P] ATP
(Amersham), for 30min at 378C in the buﬀer supplied
with the enzyme in a 30ml ﬁnal volume. Labeled tRNA
lys3
was then puriﬁed by denaturing PAGE. ODN, an 18-mer
oligodeoxyribonucleotide complementary to the PBS was
chemically synthesized and 50-end labeled for 45min at
378C using 100mCi of [g-
32P] ATP and 10U of PNK (New
England Biolabs). Internal labeling of RNA 1–615 was
achieved by addition of [a-
32P] ATP (Amersham) during
transcription (57).
Proteins
Wild-type HIV-1 Vif protein was expressed in
Escherichia coli with an N-terminal 6-His fusion tag and
puriﬁed as previously described (58). NCp7, NCp9 and
NCp15 proteins from NL4.3 (55, 72 and 122 amino acids,
respectively), expressed in E. coli and puriﬁed as described
(59), were reconstituted with one equivalent of Zn
2+ per
zinc ﬁnger in milliQ H2O (Millipore), aliquoted, layered
with mineral oil and stored at  808C (50). Wild-type and
RNase H(–) E478Q HIV-1 RTs were expressed in E. coli
with a N-terminal 6-His fusion tag and puriﬁed as
previously described (60).
Heat annealing oftRNA
Lys3and ODN
All annealing reactions were performed using 1pmol of
RNA 1–311 and 0.3pmol of 50-end labeled ODN or
tRNA
Lys3. Primer and template were denaturated 2min at
908C then cooled on ice. After addition of 0.1M NaCl and
6mM ZnCl2, samples containing ODN or tRNA
Lys3 were
incubated 20min at 50 or 708C, respectively, and cooled
on ice.
Protein-mediated tRNA
Lys3 annealing
Primer and template were ﬁrst denatured separately by
incubation 2min at 908C, ice-cooled and renaturated
10min at 378C in 50mM Tris–HCl pH 7.2, 50mM NaCl,
6mM ZnCl2 and 5mM MgCl2 (buﬀer H). RNAs were then
mixed together, incubated 10min at 378C, 5min at room
temperature and put on ice while adding Vif and/or
NC proteins. In parallel, heat-annealed complexes
were formed as described above and adjusted to 50mM
NaCl, 50mM Tris–HCl pH 7.2 and 5mM MgCl2. Heat-
and protein-mediated annealing reactions (10ml) were
incubated 20min at 378C, and split in two equal volumes,
in order to monitor hybridization and to assay extension
by wild-type HIV-1 RT. To monitor hybridization,
samples were deproteinized with 1.3mg/ml proteinase K
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33mM EDTA for 1h at 378C. Spermidine and NTPs help
minimizing aggregation of nucleic acids by NC (61).
Volume was then adjusted to 60ml with buﬀer H and
following phenol/chloroform extraction, 50mlo f
RNA-containing aqueous phase supplemented with
glycerol-containing loading buﬀer were analyzed by non-
denaturing 6% PAGE. Electrophoresis was performed
at 48C in 0.5  Tris–Borate buﬀer supplemented with
0.1mM MgCl2.
Protein-mediated RNA dimerization
In a typical experiment, 100nM of unlabeled HIV-1 1–615
RNA fragment were diluted in 10ml of Milli-Q (Millipore)
water with the corresponding labeled RNA (5000c.p.m.,
3–5nM). Samples were denatured for 2min. at 908C, and
snap-cooled on ice for 2min. Dimerization was initiated
by addition of Vif and/or NCp7 proteins in conditions
disfavoring salt-induced RNA dimerization (50mM
sodium cacodylate pH 7.5, 50mM NaCl, 0.1mM
MgCl2). RNA samples were incubated 30min at 378C
and deproteinized as above, then re-suspended in glycerol-
containing loading buﬀer, split in two equal volumes and
analyzed on a 0.8% agarose gel in native (Tris–Borate
0.5 , MgCl2 0.1mM, run at 48C) or denaturating
(Tris–Borate-EDTA 1 , run at 208C) electrophoresis
conditions. Gels were ﬁxed in 10% trichloroacetic acid
for 10min. and dried for 1h under vacuum at room
temperature. Radioactive bands corresponding to
monomeric and dimeric species were visualized and
quantiﬁed using a FLA 5000 (Fuji).
Synthesisof+6extensionproductswithwild-typeHIV-1RT
To assay extension by HIV-1 RT, heat- or protein-
annealed tRNA
Lys3/RNA 1–311 complexes were ﬁrst
treated with 1.5mg/ml proteinase K in 1.5% SDS for 1h
at 378C. After addition of 0.3M sodium acetate,
complexes were phenol/chloroform extracted and precipi-
tated in ethanol. Following centrifugation and vacuum
drying, nucleic acids pellets were mildly solubilized
in buﬀer E1 (50mM Tris–HCl pH 8.0, 50mM
NaCl, 1mM DTT, 6mM MgCl2 and 1mM
spermidine). tRNA
Lys3/RNA 1–311 complexes were
incubated 4min at 378C with 70nM HIV-1 RT and
reverse transcription was initiated by addition of dTTP,
dGTP, dCTP (100mM each) and 15mM ddATP as a
chain terminator. After 45min at 378C, poly-
merase activity was blocked by adding 20mM
EDTA, samples were phenol/chloroform extracted
and precipitated in ethanol. Puriﬁed nucleic acids were
re-suspended in urea-containing loading buﬀer and
analyzed by 8% PAGE. Radioactive bands
were visualized and quantiﬁed using a BioImager BAS
2000 (Fuji).
Synthesis of+6 extension products inthe presence ofVif
To test the inﬂuence of Vif on the initiation step of
reverse transcription, heat-annealed tRNA
Lys3/RNA
1–311 complexes were incubated 20min at 378Ci n
buﬀer H with increasing concentrations of Vif. Half of
the reaction medium was treated as described above
to monitor hybridization, then 90nM HIV-1 RT and
1mM spermidine were added on the remaining half
and after 4min incubation at 378C, reverse trans-
cription was initiated by addition of dTTP, dGTP,
dCTP (50mM each) and 7.5mM ddATP as a chain
terminator. After 20min at 378C, polymerase
activity was blocked by adding 33mM EDTA, 1% SDS
and 1mg/ml proteinase K. After proteolysis for 1h at
378C, samples were phenol/chloroform extracted and
precipitated with ethanol. Nucleic acids were re-suspended
in urea-containing loading buﬀer and analyzed by
8% PAGE.
(–)Strong-stop DNA synthesis and strandtransfer assays
For (–) strand strong-stop DNA (ssDNA) synthesis
and strand transfer experiments, we used the 50-end
labeled ODN primer annealed to donor RNA 1–311.
In both assays, NC and/or Vif proteins were incubated
with 380nM WT or E478Q HIV-1 RT for 4min at 378C
in buﬀer E2 (0.1M NaCl, 60mM Tris–HCl pH 8.0,
6mM MgCl2,5 0 mM dNTPs, 1mM DTT). In strand
transfer experiments, 2pmol of acceptor RNA were
denatured 2min at 908C, ice-cooled and re-natured
at 378C for 15min in 0.1M NaCl, 60mM Tris–HCl
pH 8.0, 6mM MgCl2. Acceptor RNA was then added
to proteins and incubated 4min at 378C in buﬀer
E2. Reverse transcription was initiated by addition
of pre-incubated primer/template complexes and
proceeded for 5–60min at 378C. Polymerization
was blocked by addition of 10mM EDTA, 1% SDS
and 2mg/ml proteinase K. Samples were treated
as described above and analyzed by 6% PAGE.
Verification and quantification of strand transfer products
To distinguish genuine strand transfer products
from self-priming products, bands containing nucleic
acids longer than ssDNA were cut out of the dried gels,
eluted at room temperature in 0.5M ammonium acetate,
0.1mM EDTA and 0.1% SDS and PCR-ampliﬁed
with sense (corresponding to nucleotides 9038–9055)
and antisense (ODN) primers. Percentage of
full-length transfer product (FL) was calculated
according to:
FLð%Þ¼
IFL
IFL þ ISS FL

  100
where IFL is the intensity of the band corresponding to
full-length transfer product and ISS FL is the sum of the
intensities of incomplete transfer products and ssDNA.
RESULTS
Vifinduces formation ofafunctional tRNA
Lys3/template
RNA complex
 Vif viruses exhibit defects in the early steps of reverse
transcription (29,36,42,43) in cells expressing
APOBEC3G/3F, and APOBEC3G has been recently
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Lys3-primed DNA
synthesis, possibly by inhibiting tRNA
Lys3 annealing to
the PBS, which occurs concomitantly to or immediately
after budding (21). Gag precursor, mature NCp7, or
maturation intermediates are thought to be the main
players of this step thanks to their RNA chaperone
activity (62). However, Vif is present in large amounts in
the assembly complexes (Vif/Gag ratio  0.5) (32) and in
stoichiometric amount with RT in the viral particles ( 100
molecules) (39) and could thus aﬀect tRNA annealing. In
favor of this hypothesis, Vif binds the 50-end region of
HIV-1 genomic RNA with high aﬃnity (Kd  45nM) and
recognizes many secondary structures in the 50-UTR,
including the PBS region (33).
To test the inﬂuence of Vif on tRNA
Lys3 placement
onto the PBS, we performed annealing experiments using
puriﬁed recombinant Vif, post-transcriptionally modiﬁed
tRNA
Lys3 and a RNA template spanning the ﬁrst 311nt
of HIV-1 genomic RNA. Hybridization was monitored
by native gel electrophoresis, and to ascertain speciﬁc
and functional placement of tRNA
Lys3 to the PBS, hybrids
were tested for their ability to initiate reverse
transcription.
In keeping with previous studies, annealing of
tRNA
Lys3 at 708C in the absence of proteins proceeded
with >80% eﬃciency (Figure 1A, lanes P  and PT )
(61,63). Remarkably, we observed that Vif was able to
signiﬁcantly promote tRNA
Lys3 annealing to the PBS at
378C, in a dose-dependent manner. While no hybrid was
observed at 378C in the absence of Vif,  10% of
tRNA
Lys3 was hybridized in the presence of 0.5mM Vif,
and a maximum of 30% of tRNA
Lys3 was annealed at
5mM Vif (Figure 1A and C).
To check the functionality of the Vif-annealed
tRNA
Lys3/RNA 1–311 complexes, we monitored
reverse transcription of the viral RNA from the annealed
tRNA
Lys3 by HIV-1 RT, after removal of Vif. Primer
extension was performed using a mixture of dCTP, dTTP,
dGTP and ddATP, which allowed addition of 6nt
to tRNA
Lys3 (Figure 1B). We observed a good correlation
between the percentage of hybrid and the amount
of +6 extension products with both heat- and Vif-
annealed complexes (Figure 1B and C), indicating
that RT can recognize these complexes and initiate
DNA synthesis. However, for both types of complexes,
the amount of +6 extension product was systematically
20% lower than the amount of hybrid, suggesting a
systematic loss of tRNA
Lys3/RNA 1–311 complexes
during protein extraction and puriﬁcation procedures.
Taken together, these results clearly show that Vif is able
to promote formation of a functional tRNA
Lys3/RNA
complex.
Vif hasan inhibitory effecton the initiation ofreverse
transcription
A recent study showed that Vif stimulates HIV-1
RT activity by enhancing both the polymerization
rate and RT binding to nucleic acids (44). Vif also
stimulates DNA synthesis through abasic sites, a property
that could play a role in counteracting APOBEC3G-
mediated deamination of proviral DNA (16,64,65).
These results suggest that Vif is a co-factor of HIV-1
RT, although these experiments were performed using
an artiﬁcial primer–template complex (44). We previously
showed that when using a RNA template corresponding
to the 50-end of the HIV-1 genomic RNA and tRNA
Lys3 as
primer, (–) strand ssDNA synthesis proceeds through two
distinct steps. Initiation corresponds to the addition of the
ﬁrst 6nt to tRNA
Lys3: during this step DNA synthesis is
distributive, while the subsequent elongation is processive
A
B
C
hybrid
tRNA3
Lys
+6 product
unextended tRNA3
Lys
0 0.2 0.5 1.8 5
0 0.2 0.5 1.8
µM Vif
µM Vif
µM Vif
5
% hybrid
% +6 product
0
10
20
30
40
50
60
80
70
0 0.2 1.8 5.0 0.5 P∆ PT∆
P∆ PT∆
P∆ PT∆
Figure 1. Vif-mediated annealing of tRNA
Lys3.( A) Bandshift assay showing heat- and Vif-mediated annealing of tRNA
Lys3 to HIV-1 RNA 1–311.
Free and annealed tRNA
Lys3 are indicated by arrowheads. P  and PT  lanes correspond to heat-annealing reaction performed in the absence and
presence of RNA 1–311, respectively. (B) After deproteinization of the complexes, tRNA
Lys3 annealed in (A) was extended with HIV-1 RT using a
mixture of dCTP, dGTP, dTTP and ddATP. (C) Quantiﬁcation of the gels shown in (A) and (B). The errors bars correspond to the mean SD of
three to six experiments.
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mer DNA complementary to the PBS (ODN) allows DNA
synthesis to start in the elongation mode (63).
To test the eﬀect of Vif on the initiation of reverse
transcription, heat-annealed tRNA
Lys3/RNA 1–311
complex was incubated with increasing concentrations
of Vif and reverse transcription was initiated by adding
RT and a mixture of dCTP, dTTP, dGTP and ddATP
that allowed to complete the initiation phase of reverse
transcription (see Experimental Procedures section)
(Figure 2). Note that contrary to the +6 extension
assay described above, Vif was present during DNA
synthesis. Whereas increasing concentrations of Vif had
no eﬀect on the stability of heat-annealed hybrid
(Figure 2B), we observed a dose-dependent decrease
in +6 extension product correlated with an increase
in unextended tRNA
Lys3 primer (Figure 2A). We
did not observe any reverse transcription product
between these two forms, indicating that inhibition of
reverse transcription takes place before the addition of
the ﬁrst deoxynucleotide. These data suggest that Vif
decreased initiation of reverse transcription either by
inhibiting the addition of the incoming nucleotide or
by preventing binding of RT to the tRNA
Lys3/RNA
1–311:RT complex.
Vif stimulates (–)strand ssDNAsynthesis
In order to test the eﬀect of Vif on the elongation phase of
reverse transcription, we primed ssDNA synthesis with an
ODN annealed to the PBS of RNA 1–311. Whereas a low
(0.2mM) concentration of Vif had no signiﬁcant eﬀect on
ssDNA synthesis, a 2mM concentration of Vif increased
ssDNA synthesis by  2-fold after a 60-min reaction
time (Figure 3). Analysis of the reverse transcription
products by denaturing PAGE showed that the increase
in DNA synthesis correlated with a decrease in RT
pausing (Figure 3A, asterisks), suggesting that
Vif-enhanced ssDNA synthesis by facilitating reverse
transcription through stable secondary structures present
in the RNA template. Indeed, secondary structures slow
down RT, inducing dissociation of the enzyme
and subsequently pauses (68,69). Thus, our data suggest
that stimulation of ssDNA synthesis results from
Vif–RNA interactions.
Effects of NC intermediates and Vif on viralRNA
dimerization, tRNA
Lys3annealing and (–)ssDNA synthesis
Mature NCp7 is a well-characterized co-factor of
HIV-1 RT (70), and at least some of the Vif-binding
sites in the 50 region of viral RNA are also NCp-binding
unextended tRNA3
Lys
+6 product
µM Vif A
B
hybrid
tRNA3
Lys
P∆ PT∆
P∆ PT∆
0 0.075 0.225 0.750
mM Vif 0 0.075 0.225 0.750
Figure 2. Eﬀect of Vif on the initiation of reverse transcription. Heat-
annealed tRNA
Lys3/RNA 1–311 complex (PT ) was incubated with
HIV-1 RT and increasing concentrations of Vif. (A) Reverse
transcription was initiated by addition of dTTP, dGTP, dCTP and
ddATP. Polymerization was blocked with EDTA after 20min.
Following deproteinization, samples were analyzed by denaturing
PAGE to visualize the initiation product (tRNA
Lys3 extended by
6nt). (B) Native PAGE control showing that Vif did not destabilize the
heat-annealed complex.
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Figure 3. Eﬀect of Vif on (–) strand strong-stop DNA synthesis.
A DNA primer (ODN) heat-annealed to RNA 1–311 was extended by
incubating with HIV-1 RT, Vif and dNTPs. Polymerization was for 5,
20 or 60min and the samples were deproteinized before PAGE.
(A) Denaturing gel showing the time course of labeled ODN extension
in the presence of increasing concentrations of Vif. Minus strong-stop
DNA and unextended ODN are indicated. Asterisks indicate RT
pauses speciﬁcally reduced by the addition of Vif. (B) Quantiﬁcation of
(A), data is normalized to the ratio of ssDNA synthesized at 60min in
the absence of Vif. The errors bars correspond to the mean SD
of three to six experiments.
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Lys3 annealing
and ssDNA synthesis have been well documented (62),
the combined eﬀects of Vif and NC on these steps have
never been studied. Furthermore, as Vif has been shown
to modulate processing of the Gag precursor (47), we also
studied the eﬀects of NCp9 and NCp15, together with Vif,
on these steps. Primer tRNA
Lys3 annealing and extension
experiments were performed as described above, except
that NC proteins were present at a concentration
corresponding to complete coverage of the RNA template
(1NCp/5nt) (71) (Figure 4). In the absence of Vif, this
saturating concentration of NCp allowed very eﬃcient
hybridization of tRNA
Lys3 to the PBS, with a maximum
of 90% hybrids with NCp9 and NCp15 and a slightly
reduced eﬃciency with NCp7 (70% hybrids) (Figure 4B,
yellow bars), in agreement with previous studies (61),
Unexpectedly, increasing Vif concentrations had an
inhibitory eﬀect on the formation of tRNA
Lys3/vRNA
hybrids induced by NCp (Figure 4A and B, yellow bars),
with a corresponding decrease in +6 product formation
(Figure 4B, blue bars).
Moreover, while the tRNA
Lys3/vRNA complex formed
by heating or in the presence of Vif migrated as a single
band, two tRNA
Lys3/vRNA complexes could be observed
in the presence of NC proteins, with the main one
migrating slower than the complex formed in the presence
of Vif (Figure 4A). These two bands correspond to
tRNA
Lys3 annealed to monomeric and dimeric forms of
HIV-1 RNA. Indeed, when using a fragment of HIV-1
genomic RNA with point mutations (AAA) in the
dimerization initiation site (DIS), which is crucial for
RNA dimerization (51,52), the monomeric form of the
hybrid became largely predominant, even in the presence
of NCp7 (Figure 4A, right panel). Interestingly, increasing
µM Vif
NCp7 / nt 1/5
monomer
dimer
hybrid
tRNA
Lys3
5 0 0.2 0.5 1.8 5 0 0.2 0.5 1.8
no NCp7 NCp7
WT AAA WT AAA
A
B
µM Vif
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0 0.2 0.5 1.8 5
0
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30
40
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90
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1 NC/5nts
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0 0.2 0.5 1.8 5
NCp15
0 0.2 0.5 1.8 5
% dimer/hybrid
% hybrid
% +6 product
P∆ PT∆ P∆
PT∆
Figure 4. Eﬀect of Vif on NCp-mediated tRNA
Lys3 annealing and RNA dimerization. (A) Bandshift assay showing heat- (PT ) and
NCp-mediated annealing of tRNA
Lys3 to HIV-1 RNA 1–311 in presence of increasing concentration of Vif. Free and annealed tRNA
Lys3
on monomeric or dimeric 1–311 RNAs are indicated. P  and PT  lanes correspond to heat-annealing reaction performed in the absence
and presence of RNA 1–311, respectively. (B) Quantiﬁcation of the data: blue bars, % of +6 product; purple bars, % of tRNA
Lys3 annealed to
dimeric RNA/tRNA
Lys3 annealed to monomeric+dimeric RNA; yellow bars, % of tRNA
Lys3 annealed to monomeric+dimeric RNA.
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RNA dimerization, and inhibition was almost complete at
the highest Vif concentrations (Figure 4A, left panel). Vif
had similar eﬀects when tRNA
Lys3 annealing and HIV-1
RNA dimerization were induced by NCp15, i.e. Vif
eﬃciently inhibited both processes (Figure 4B right
panel). However, tRNA
Lys3 annealing and especially
HIV-1 RNA dimerization promoted by NCp9 were
more resistant to inhibition by Vif (Figure 4B, central
panel).
These results prompted us to analyze more precisely the
capacity of Vif to modulate HIV-1 RNA dimerization in
the absence of tRNA
Lys3 and in absence or in presence of
NCp7 (Figure 5). Indeed, HIV-1 RNA can form two
diﬀerent kinds of dimers in vitro, termed loose and tight
dimers (51). Loose dimers are formed ﬁrst and correspond
to kissing complexes interacting by the DIS loop
(57,72,73). Formation of tight dimers depends on the
presence of the sequences 30 to the major splice donor site,
the incubation temperature and the presence of NCp.
Although several authors have proposed that tight dimers
could correspond to extended duplexes, this has not been
demonstrated conclusively on large RNA fragments, and
alternatively the kissing complexes could be stabilized by
tertiary interactions that remain to be identiﬁed (51).
Using an RNA fragment encompassing the ﬁrst 615nt of
HIV-1 genomic RNA, we analyzed dimerization using two
diﬀerent electrophoresis conditions: (i) native electrophor-
esis in Tris–Borate magnesium (TBM) buﬀer at 48C,
under which both loose and tight dimers are stable
(Figure 5A) and (ii) semi-denaturing electrophoresis in
Tris–Borate-EDTA (TBE) buﬀer at room temperature,
under which only the tight dimers survive (Figure 5B) (72).
In the absence of NCp, Vif stimulated RNA dimerization
in a concentration dependant manner, and a dimerization
yield of 30% was observed at 5mM Vif (Figure 5A).
This Vif–induced RNA dimer is a loose dimer, as it
dissociated during electrophoresis under semi-denaturing
conditions (Figure 5B) (57,72,73). In the absence of Vif, a
saturating NCp concentration induced >90% RNA
dimerization, and the NCp-induced dimer was predomi-
nantly the tight dimer (compare Figure 5A and B), in
keeping with previous studies (72,74). However, increasing
Vif concentration progressively decreased the dimerization
yield from >90% to  50% (Figure 5A), and the RNA
dimer remaining at the highest Vif concentration was
exclusively the loose dimer (compare Figure 5A and B).
Thus, Vif was able to promote formation of the loose
dimer, and to inhibit formation of the tight dimer by NCp,
indicating that, as in the tRNA
Lys3 annealing experiments,
the eﬀect of Vif was dominant over NCp. Taken together,
these results suggest that the dominant eﬀect of Vif over
NC proteins is due to Vif/NC interactions, rather than
to Vif–RNA interactions.
Next, we compared the eﬃciency of ssDNA synthesis
in the presence of NCp15, NCp9 and NCp7 (Figure 6).
At a concentration of 1NCp/5nt, a  4.5-fold increase
of ssDNA was observed with NCp9 after 60min of
reaction, which correlated with a strong decrease in
the intensity of RT pauses (Figure 6, middle panel,
black triangles). Comparatively, NCp7 and NCp15 had
a smaller stimulatory eﬀect ( 2.5 and  3-fold,
respectively) and less inﬂuence on RT pausing (Figure 6).
Given the stimulatory eﬀect of Vif on ssDNA synthesis
(Figure 3B), we tested whether Vif could act synergistically
with NC to increase the yield of ssDNA. Compared with
DNA synthesis performed with NC or Vif alone, reactions
performed in the presence of both Vif and NC showed no
signiﬁcant synergy. Addition of 2mM Vif to reactions
containing saturating amounts of NC signiﬁcantly delayed
ssDNA synthesis, and similar yields of ssDNA were
observed only at the last time point (60min) (Figure 6).
However, RT pauses speciﬁcally induced by either NCp7
or NCp15 (Figure 6, left and right panels, asterisks) were
strongly diminished in the presence of 2mM Vif. Note that
NCp7 and NCp15 generated diﬀerent pausing patterns,
suggesting that these two proteins preferentially bind to
diﬀerent RNA motifs in the R region, but that Vif had
similar eﬀects in these two reactions. These results suggest
that both NC and Vif contributed to increase the
processivity of RT and that NC–RNA interactions are
aﬀected by Vif binding to RNA.
Stimulation ofthe first strand transfer by Vif andNC
intermediates
The presence of repeated (R) sequences at both ends of
retroviral genomes allows transfer of the neo-synthesized
ssDNA from the 50 to the 30-terminal region of the viral
RNA (75). It has been shown that the ﬁrst strand transfer
is strongly enhanced by NCp9 and NCp7 in vitro
(62,76,77), and interactions between NC and the TAR
loop of the viral RNA or its complement cTAR on the
ssDNA play an important role in this process (49,78). As
we recently showed that the TAR apical loop is a high
aﬃnity Vif-binding site (33) (Bernacchi et al., in press
for publication), we tested the inﬂuence of Vif on the ﬁrst
1/5
0 0.2 2.0 5.0 0 0.2 2.0 5.0
no NCp7 B
A
0 0.2 2.0 5.0 0 0.2 2.0 5.0
1/5 no NCp7
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NCp7 / nt
µM Vif
NCp7 / nt
TBM @ 4°C
TBE @ 25°C
Figure 5. Vif and NC-mediated HIV-1 RNA dimerization in vitro.
HIV-1 RNA 1-615 (100nM) was allowed to dimerize in vitro with
Vif (0, 0.2, 2.0 and 5.0mM) in absence or in presence of NCp7
protein (saturating concentration, 6mM). After removal of Vif and
NCp7, RNA was loaded on an agarose gel and run in (A) native
(Tris–Borate-Magnesium, TBM, at 48C) and (B) semi-denaturing
(Tris–Borate-EDTA, TBE, at 258C) electrophoresis conditions.
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the donor template, and RNA 8607–9229 as the acceptor
RNA, as previously described (53).
During ssDNA synthesis, as the RNA template is being
degraded by RNase H, the cTAR sequence in ssDNA can
fold into a hairpin structure that is able to ‘self-prime’
reverse transcription, yielding abortive products that are
longer than ssDNA. First, we used an RNase H(–) HIV-1
RT that is unable to give rise to strand transfer and
self-priming products to unambiguously identify ssDNA
(Figure 7A, ﬁrst lane). Longer products were observed
with wild-type RT in the presence of acceptor RNA but in
the absence of Vif or NC proteins. These were self-priming
products, since PCR ampliﬁcation of the corresponding
gel-eluted nucleic acid bands did not yield any products
when using primers speciﬁc to strand-transfer products
(see Experimental Procedures section, data not shown).
On the other hand, strand transfer reactions performed
with wild-type RT and increasing Vif concentrations yield
a faint but reproducible product near the top of the gel,
identiﬁed as full-length strand transfer product by PCR
(Figure 7A). Quantiﬁcation showed that  5% of the
ssDNA was converted into full-length transfer product in
the presence of 2mM Vif. Thus, Vif can stimulate the
strand transfer reaction, albeit with a limited eﬃciency.
In the absence of Vif and in the presence of a saturating
concentration of NC proteins, strand transfer proceeded
with varying eﬃciency, depending on the protein: the
unextended
ODN
(−) strong-stop
DNA
Vif (µM)
1/5 NCp7 1/5 NCp15 NC / nt
52 0
0 0.2 2
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*
Figure 6. Minus strong-stop DNA synthesis in the presence of Vif and NC proteins. ODN extension products were analyzed by denaturing
PAGE. Asterisks indicate RT pauses speciﬁcally induced by the diﬀerent NC proteins and suppressed by high concentration of Vif proteins.
Black triangles indicate RT pauses speciﬁcally suppressed by high concentration of NC proteins. The NC coverage of 1NCp/5nt corresponds to
a concentration of 6mM of NCp.
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 25% of full-length transfer product, while NCp15 and
NCp9 were less potent ( 14% and  8% of full-length
product, respectively) (Figure 7). This result clearly shows
that mature NCp7 promotes strand transfer more
eﬃciently than NC maturation intermediates, probably
due to the diﬀerent nucleic acids chaperone and aggregat-
ing activities of these proteins (59). Adding increasing
concentrations of Vif to a saturating concentration of NC
led to a dose-dependent modulation of NCp7 and NCp15
activity, while no eﬀect was observed on NCp9. Although
Vif moderately decreased the amount of full-length
transfer product in NCp7-mediated transfer reaction, Vif
showed an opposite eﬀect in presence of NCp15, where
addition of 2mM of Vif reproducibly increased the yield of
full-length transfer product by  40%. Taken together,
these results show that Vif alone slightly promote the ﬁrst
strand transfer reaction and that this protein is able to
speciﬁcally modulate the activity of NCp7 and NCp15 in
this process.
DISCUSSION
Several reports demonstrated that deletion of the vif
gene aﬀected reverse transcription during the
entry phase of the viral life cycle (39,40,42,44) and
prevented endogenous reverse transcription (29,36,43),
suggesting that Vif could interact with virion components
involved in the regulation of reverse transcription such as
RT (44), NC (31,32), tRNA
Lys3 (29,79) and genomic RNA
(28–30,33). However, the molecular mechanisms of
Vif function in reverse transcription have remained
unclear. Since we recently showed that Vif is an
RNA-binding protein that preferentially binds to the
50 terminal region of HIV-1 genomic RNA, including the
PBS, we decided to examine for the ﬁrst time the in vitro
contribution of Vif to the initial steps of reverse
transcription, either alone or in combination with NC
proteins at diﬀerent maturation stages. In addition, since
Vif is present in the HIV-1 assembly complexes (32), we
studied the eﬀect of Vif on RNA dimerization, as this step
is a prerequisite to eﬃcient HIV-1 RNA packaging (51).
In order to analyze the intrinsic properties of Vif, we ﬁrst
studied this protein in the absence of other viral proteins.
Then, to evaluate the potential biological signiﬁcance of
our results, we studied the eﬀects of Vif in the presence
of NC proteins.
In the absence of NC proteins, Vif enhances several
early steps of the reverse transcription process. First, Vif is
able to anneal tRNA
Lys3 to a PBS-containing RNA
fragment quite eﬃciently (Figure 1A), even though Vif is
less eﬃcient than NCp7, NCp9 and NCp15 in this respect
(Figure 4B). In addition, the resulting primer–template
complex is fully functional, since HIV-1 RT was able to
initiate reverse transcription of these complexes
(Figure 1B). The annealing activity of Vif might be
important for HIV-1 replication in non-permissive cells,
since it was recently shown that inhibition of
tRNA
lys3-primed reverse transcription of  Vif viruses by
APOBEC3G and 3F accounts for an important part
of its antiviral eﬀect, independently of its deaminase
activity (21,80).
Second, Vif signiﬁcantly decreases pausing of RT and
enhances ssDNA synthesis (Figure 3). RT pausing most
often occurs when RT is blocked by stable secondary
structures present in the RNA template (68,69). Indeed,
we previously showed that Vif binds to several
secondary structure motifs in the R and U50 regions of
the genomic RNA (33), and our present results suggest
that Vif is able to destabilize these structures, allowing a
better processivity of HIV-1 RT. The eﬀect of Vif on RT
EQ
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Figure 7. Eﬀects of Vif and NC proteins on the ﬁrst strand transfer. (A) PAGE analysis of transfer products. ODN/RNA 1–311 complexes were
incubated with RT, dNTPs, acceptor RNA, Vif and/or NC proteins (6mM). A control using RNase H(–) E478Q HIV-1 RT is shown in ﬁrst lane.
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RT for the primer–template complex in the presence
of Vif, as observed by Cancio et al. (44) using poly(rA)/
oligo(dT). Even though the exact mechanism by which Vif
increases RT processivity remains to be established, this
activity is analogous to the previously described eﬀect
of NCp7 on RT pausing (62,68).
We also reproducibly observed that Vif stimulates the
ﬁrst strand transfer, albeit with a reduced eﬃciency
compared to NC proteins: Vif was 2-fold less eﬃcient
than NCp9, 3-fold less eﬃcient than NCp15 and 5-fold
less eﬃcient than NCp7 (Figure 7). Nevertheless, Vif
shares with NC proteins the ability to anneal tRNA
Lys3 to
the PBS, decrease RT pausing, and promote strand
transfer. These properties, especially the ﬁrst and the
third one, are characteristic of the RNA chaperone
activity of NC proteins (59). In addition, we found that
Vif, like NCp (74), promotes dimerization of HIV-1 RNA,
even though the former induces formation of loose dimers,
while the latter favors tight dimers. Therefore, our results
show that Vif is an authentic RNA chaperone (81).
These results prompted us to look for potential synergic
eﬀects between Vif and various Gag processing products
such as NCp15, NCp9 and NCp7. Processing of the Gag
precursor takes place in a sequential manner during
maturation of HIV-1 viral particles due to diﬀerences in
cleavage site eﬃciency (82). Cleavage starts at the p2/NC
junction, resulting in the production of MA-CA-p2 and
NCp15 intermediates products. Secondary cleavage
releases the mature MA protein as well as the
NCp9 (NCp7-p1) intermediate after removal of p6 (83).
Tertiary cleavage produces mature CA and NCp7
proteins. Mature viral particles are not only composed
of fully processed Gag and Gag-Pol products, but
also contain residual amounts of Gag precursors and
processing intermediates (47). Moreover, Vif modulates
the HIV-1 protease activity, leading to the possibility that
virion incorporation of Vif could stabilize NC intermedi-
ates (45–47). A number of molecular rearrangements
occur in the RNP during or just after budding, including
tRNA
Lys3 hybridization (70), RNA dimer maturation (84)
and initiation of reverse transcription (70).
In the tRNA
Lys3 annealing reactions, Vif clearly has a
dominant eﬀect over NC proteins (Figure 4). Indeed,
increasing concentrations of Vif signiﬁcantly inhibited
NC-induced tRNA
lys3 annealing (Figure 4B) and RNA
dimerization (Figures 4A and 5). This inhibitory eﬀect of
NC-mediated functions might explain why excessive Vif
expression is detrimental to viral infectivity (47).
Importantly, the highest Vif concentration used in this
study corresponds to a Vif/NCp ratio of 1/3, which is close
to the 1/2 Vif/Gag ratio in the assembly complexes (32,39).
Thus, Vif might initiate tRNA
lys3 annealing in the
assembly complexes, and since it is mostly excluded
from the virions (the Vif/NCp ratio in virions is between
1/20 and 1/40), its inhibitory eﬀect would be relieved
after assembly of the virions, and NC proteins could
complete tRNA
Lys3 annealing. In this context, inhibition
of the initiation of reverse transcription by Vif (Figure 2)
might prevent premature initiation of DNA synthesis
in the assembly complexes of the producing cell.
Interestingly, identical eﬀects have been observed with
the Tat protein (85,86). Similarly, inhibition of the
NC-induced viral RNA dimerization by Vif (Figure 5)
might temporally regulate RNA packaging and prevent
premature maturation of the loose kissing loop complex
into a more thermostable tight dimer. Thus, our results
suggest that Vif is a negative regulator of several NCp-
associated functions in the assembly complexes, and that
the NC domain (either in Gag or its maturation product)
becomes fully active in the viral particles, from which Vif
is mostly excluded. Inhibition of the NCp-mediated
tRNA
lys3 annealing and RNA dimerization, as well as
inhibition of the initiation of reverse transcription by Vif
might allow temporal ﬁne-tuning of these steps.
During ssDNA synthesis, both Vif and NC proteins
decreases RT pausing. However, NC proteins also appear
to induce pausing at sites that were speciﬁc for each NC
species (Figure 6). These pauses could result from
increased RNase H activity of RT in the presence of NC
proteins (62). No additional pauses were observed with
Vif; on the contrary Vif suppressed the NC-induced
pauses. Thus, Vif act in cooperation with NC proteins to
increase RT processivity and favor synthesis of long DNA
products.
The eﬀect of Vif on NC-induced strand transfer is
limited, but, unexpectedly, Vif has either a positive, null or
negative eﬀect depending on the maturation stage of NC
proteins (Figure 7). Signiﬁcantly, NCp9 is the most
eﬃcient NC species in ssDNA synthesis, whereas NCp7
has the most eﬃcient strand transfer activity, suggesting
that maturation of the NC intermediates might regulate
the early steps of HIV-1 reverse transcription.
Thus far, it was unclear whether Vif has a direct role in
reverse transcription. Our data strongly suggest that Vif
does play a role during the early phase of this process in
coordination with other components of the viral core such
as Gag and its maturation products and during the
dimerization of genomic RNA. Taken together, our data
lead to the possibility that Vif might be a temporal
regulator during viral assembly: (i) by interacting with
genomic RNA and NC-derived products, Vif may prevent
RNA dimerization/packaging and premature initiation of
reverse transcription; (ii) however, still in conjunction with
Gag precursors, Vif could promote the placement of
tRNA
Lys3 on to the PBS, stabilizing NC intermediates to
increase, at the right time, the eﬃciency of the early steps
of reverse transcription. Obviously, a detailed temporal
analysis of the eﬀects of Vif on HIV-1 replication will be
required to test our hypothesis.
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